VEGFA and intrahepatic cholangiocarcinoma: Bevacizumab, a VEGF inhibitor, has been evaluated in advanced biliary tract cancers in combination with chemotherapy, which resulted in an overall response rate of 41% with a median PFS of 7.6 months and a median OS of 14.2 months in patients with ICC [12].